《Harris Williams：2022年第四季度外包制药服务与制药技术行业更新报告（英文版）（18页）.pdf》由会员分享，可在线阅读，更多相关《Harris Williams：2022年第四季度外包制药服务与制药技术行业更新报告（英文版）（18页）.pdf（18页珍藏版）》请在三个皮匠报告上搜索。

1、Outsourced Pharma Services&Pharma Tech Sector Update Harris Williams|Q4 2022Outsourced Pharma Services and Pharma Tech|Q4 2022Biopharmaceutical companies increasingly rely on technology and service vendors to accelerate research and development and time to market as well as optimize commercial succe

2、ss of therapies.2Outsourced Pharma Services and Pharma Tech:Observations and Key TrendsDiscoveryResearch&DevelopmentLaunchPost-Launch/In-MarketAs target populations reduce in size and cost of commercialization increases,pharma is increasingly focused on solutions that keep patients engaged and adher

3、ent to their course of care.Targeting AdherenceThe indications that pharma is targeting for new therapies are becoming increasingly complex and focused,resulting in higher overall discovery and development costs.These therapeutics,which are more frequently large molecule,are targeting significantly

4、smaller,more complex patient populations,making it more difficult and costly to recruit and retain patients in clinical trials.Increasing Complexity and Cost of R&D ProcessReal-world evidence(RWE)and data is playing an increasingly crucial role in clinical and commercialization stages of development

5、,helping pharma manufacturers quickly and effectively bring therapies to market and identify and prove out additional indications.Focus on RWEAs pharmaceutical products become increasingly specialized and more costly,payors are pushing back and requiring robust outcomes evidence to support reimburse

6、ment.Challenges With PayorsLegacy Commercialization Approaches Are No Longer EffectiveAs many blockbuster pharmaceuticals approach the end of their patented life and face generic competition,pharma manufacturers are targeting growth through niche opportunities with smaller addressable markets.Effect